0001654954-19-000217.txt : 20190108 0001654954-19-000217.hdr.sgml : 20190108 20190107184803 ACCESSION NUMBER: 0001654954-19-000217 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190108 DATE AS OF CHANGE: 20190107 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AzurRx BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-89966 FILM NUMBER: 19514315 BUSINESS ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 BUSINESS PHONE: 646-699-7855 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Ross Edmund Burke Jr. CENTRAL INDEX KEY: 0001682557 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: C/O JDJ FAMILY OFFICE SERVICES STREET 2: P.O. BOX 962049 CITY: BOSTON STATE: MA ZIP: 02196 SC 13D/A 1 sc13d.htm SCHEDULE 13D/A Unassociated Document
 
 
 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
SCHEDULE 13D/A
(Amendment No. 1)* 
 
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
 
Under the Securities Exchange Act of 1934
 
 
AzurRx BioPharma, Inc.
(Name of Issuer)
 
 
Common Stock
(Title of Class of Securities)
 
 
05502L105
(CUSIP Number)
 
 
December 27, 2018
(Date of Event Which Requires Filing of this Statement)
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ] 
 
 
 
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 
 
 
 
 
 
   
 CUSIP No. 05502L105
13D/A
 
 

1             NAMES OF REPORTING PERSONS
               Edmund Burke Ross Jr.
 

2             CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐
 

3             SEC USE ONLY
 

4             CITIZENSHIP OR PLACE OF ORGANIZATION
              
               USA
 

NUMBER OF
SHARES
5
SOLE VOTING POWER
0
BENEFICIALLY
6
SHARED VOTING POWER
0
  OWNED BY
EACH REPORTING
7
SOLE DISPOSITIVE POWER
0
REPORTING PERSON WITH 
8
SHARED DISPOSITIVE POWER
0
 

9             AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
               2,540,555
 

10           CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
               ☐
 

11            PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
                15.0%(1)
 

12            TYPE OF REPORTING PERSON
                 IN
 

  
(1) 
Based on 16,940,462 shares of common stock (“Common Stock”) outstanding as of November 8, 2018, as reported in the Issuer’s Quarterly Report on Form 10-Q (the “Form 10-Q”), filed on November 9, 2018.
 
 
 
 
 
 CUSIP No. 05502L105
13D/A
 
 
 

1             NAMES OF REPORTING PERSONS
               EBR Ventures, LLC
 

2             CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐


3             SEC USE ONLY
 

4             CITIZENSHIP OR PLACE OF ORGANIZATION 
                Delaware
 

 
NUMBER OF
SHARES
5
SOLE VOTING POWER
0
BENEFICIALLY
6
SHARED VOTING POWER
0
  OWNED BY
EACH REPORTING
7
SOLE DISPOSITIVE POWER
0
REPORTING PERSON WITH 
8
SHARED DISPOSITIVE POWER
0
 

9               AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                 794,545
 

10             CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
                 ☐
 

11             PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9        
                 4.7% (1)
 

12             TYPE OF REPORTING PERSON 
                 OO
 

 
(1) 
Based on 16,940,462 shares of Common Stock outstanding as of November 8, 2018, as reported in the Form 10-Q.
 
 
 
 
 
 
 CUSIP No. 05502L105
13D/A
 
 
 

1             NAMES OF REPORTING PERSONS 
               ADEC Private Equity Investment, LLC 
 

2             CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
               (a) ☐
               (b) ☐
 

3             SEC USE ONLY
 

4             CITIZENSHIP OR PLACE OF ORGANIZATION
               Delaware
 

 
NUMBER OF
SHARES
5
SOLE VOTING POWER
0
BENEFICIALLY
6
SHARED VOTING POWER
0
  OWNED BY
EACH REPORTING
7
SOLE DISPOSITIVE POWER
0
REPORTING PERSON WITH 
8
SHARED DISPOSITIVE POWER
0
 

9              AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 
                1,676,009 
 

10             CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 
                 ☐
 

11             PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 
                 9.9% (1)
 

12             TYPE OF REPORTING PERSON 
                 OO
 

 
(1) 
Based on 16,940,462 shares of Common Stock outstanding as of November 8, 2018, as reported in the Form 10-Q.
 
 
 
 
 
 
 CUSIP No. 05502L105
13D/A
 
 

1             NAMES OF REPORTING PERSONS 
               CEDA Investments, LLC
 

2             CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐ 
 

3             SEC USE ONLY 
 

4             CITIZENSHIP OR PLACE OF ORGANIZATION
                Delaware
 

 
NUMBER OF
SHARES
5
SOLE VOTING POWER
0
BENEFICIALLY
6
SHARED VOTING POWER
0
  OWNED BY
EACH REPORTING
7
SOLE DISPOSITIVE POWER
0
REPORTING PERSON WITH 
8
SHARED DISPOSITIVE POWER
0
 

9               AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 
                 70,001
 

10             CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 
                 ☐
 

11             PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 
                 0.4% (1)
 

12             TYPE OF REPORTING PERSON 
                 OO


 
(1) 
Based on 16,940,462 shares of Common Stock outstanding as of November 8, 2018, as reported in the Form 10-Q.
 
 
 
 
 
Item 1. Security and Issuer
 
This Amendment No. 1 amendments the statement on Schedule 13D originally filed with the U.S. Securities and Exchange Commission on June 13, 2017 (together, this “Schedule 13D”). This Schedule 13D relates to shares of common stock, $0.0001 par value per share (the “Common Stock”), of Azur Rx BioPharma, Inc., a Delaware corporation (the “Issuer”), whose principal executive offices are located at 760 Park Side Avenue, Downstate Biotechnology Incubator, Suite 304, Brooklyn, NY 11226.
 
Item 3. Source and Amount of Funds or Other Consideration
 
Item 3 of the Schedule 13D is hereby amended and restated as follows:
 
The securities reported in this statement were acquired with funds provided form working capital of the Reporting Persons who directly beneficially own such securities.
 
Item 4. Purpose of Transaction
 
Item 4 of the Schedule 13D is hereby amended and restated as follows:
 
The Reporting Persons purchased the securities reported in this statement for investment purposes. The Reporting Persons do not have any current plans, proposals or negotiations that relate to or would result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons review their investments on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position, the price levels of the shares of Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may, in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, purchasing additional shares of Common Stock, selling shares of Common Stock, engaging in short selling of or any hedging or similar transaction with respect to the Common Stock, taking any other action with respect to the Issuer or any of its securities in any manner permitted by law or changing its intention with respect to any and all matters referred to in paragraphs (a) through (j) of Item 4.
 

 
 
 
   
Item 5. Interest in Securities of the Issuer
 
Item 5 of the Schedule 13D is hereby amended and restated as follows:
 
(a), (b), and (c) As of January 7, 2019, the Reporting Persons beneficially owned in the aggregate 2,540,555 shares of Common Stock, constituting approximately 15.0% of the outstanding Common Stock. The following table sets forth certain information with respect to shares of Common Stock directly beneficially owned by the Reporting Persons listed below:
 
Name
 
Number of Shares of Common Stock
 
 
 
 
 
Percentage of Outstanding Common Stock
 
Edmund Burke Ross Jr.
  2,540,555 
(1)
  15.0%
EBR Ventures, LLC
  794,545 
(2)
  4.7%
ADEC Private Equity Investment, LLC
  1676,009 
(2)
  9.9%
CEDA Investments, LLC
  70,001 
(2)
  0.4%
 
(1) 
Includes warrants to purchase 741,170 shares of Common Stock beneficially owned by Mr. Ross, of which warrants to purchase 75,000 shares of Common Stock are owned by EBR Ventures, LLC, warrants to purchase 644,741 shares of Common Stock are owned by ADEC Private Equity Investment, LLC, and warrants to purchase 21,429 shares of Common Stock are owned by CEDA Investments, LLC.
(2) 
Includes warrants to purchase shares of common stock in amount specified in footnote (1).
 
Mr. Ross is the manager of EBR Ventures, LLC, ADEC Private Equity Investment, LLC, and CEDA Investments, LLC and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of the Common Stock that EBR Ventures, LLC, ADEC Private Equity Investment, LLC, and CEDA Investments, LLC own. Mr. Ross has the sole power to vote or direct the vote or to dispose of 2,540,555 shares of Common Stock. None of EBR Ventures, LLC, ADEC Private Equity Investment, LLC, and CEDA Investments have power to vote or direct the vote or to dispose any shares of Common Stock.
 
Beneficial ownership of the Common Stock shown on the cover pages of and set forth elsewhere in this statement for each of the Reporting Persons assumes that they have not formed a group for purposes of Section 13(d)(3) under the Exchange Act, and Rule 13d-5(b)(1) promulgated thereunder. If the several Reporting Persons were deemed to have formed a group for purposes of Section 13(d)(3) and Rule 13d-5(b)(1), the group would be deemed to own beneficially (and may be deemed to have shared voting and dispositive power over) in the aggregate 2,540,555 shares of Common Stock, constituting approximately 15.0% of the outstanding shares of Common Stock.
 
The filing of this Schedule 13D and any future amendment by the Reporting Persons, and the inclusion of information herein and therein with respect to Mr. Ross, EBR Ventures, LLC, ADEC Private Equity Investment, LLC, and CEDA Investments, LLC, shall not be considered an admission that any of such persons, for the purpose of Section 16(b) of the Exchange Act, are the beneficial owners of any shares in which such personsdo not have a pecuniary interest. Mr. Ross holds sole voting and dispositive power over the shares of common stock and each of ADEC Private Equity Investment, LLC, EBR Ventures, LLC, and CEDA Investments, LLC disclaims beneficial ownership of such securities and securities underlying the warrants, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that any of ADEC Private Equity Investment, LLC, EBR Ventures, LLC, or CEDA Investments, LLC is the beneficial owner of such securities for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
 
The percentage of shares of Common Stock reported as being beneficially owned by the based on 16,940,462 shares of Common Stock outstanding as of November 8, 2018, as reported in the Form 10-Q.
 
The Reporting Persons have acquired shares of Common Stock during the last 60 days as follows:
 
Name                                            
Date         
        Transaction 
No. of Shares                             Price per Share
   
EBR Ventures, LLC
12/27/2018                       
Purchase                       
42,922                                            
$ 1.18
 
EBR Ventures, LLC
12/27/2018                       
Purchase                       
23,200                                            
$ 1.13
 
EBR Ventures, LLC
12/28/2018                       
Purchase                       
29,575                                            
$ 1.18
 
EBR Ventures, LLC
12/31/2018                       
Purchase                       
23,848                                            
$ 1.22
 
In addition, CEDA Investments, LLC purchased 20,000 shares at $2.50 per share on May 2, 2018.
 
(d) and (e) Not applicable.
 
 
 
 
 
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
Dated: January 7, 2019
EDMUND BURKE ROSS, JR.
 
 
By:
 
/s/ Edmund Burke Ross, Jr. for himself, as manager of ADEC Private Equity Investment, LLC, as manager of EBR Ventures, LLC, and as manager of CEDA Investments, LLC
 
 
Name:
 
Edmund Burke Ross, Jr.
 
Title:
Manager